Matsuno H, et al. - Researchers, herein, focused on the similarities between LBEC0101 (etanercept biosimilar) and the etanercept reference product (ETN-RP) in terms of efficacy and safety, including immunogenicity, in patients with active rheumatoid arthritis despite methotrexate treatment. They found that both LBEC0101 and ETN-RP displayed relatively equivalent clinical efficacy. Moreover, they noted that, with good tolerability, LBEC0101 had a comparable safety profile to ETN-RP.